+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.

Age: 18Years - 100YearsAll Genders
287 locations
O

Actively Recruiting

This research investigates participant satisfaction with subcutaneous SC ocrelizumab treatment in people with Multiple Sclerosis MS. It focuses on measuring satisfaction after 12 months of therapy using a specialized questionnaire called the Therapy Administration Satisfaction Questionnaire Subcutaneous TASQ-SC. The study also examines changes and correlations in neurofilament light chain NfL protein levels, a marker related to MS disease activity. Participants who are receiving ocrelizumab SC injections for the first time as part of their routine MS treatment will be observed for up to 12 months. The treatment is given according to the physicians discretion and local clinical practice. Throughout the study, participant satisfaction with the SC injection will be assessed at baseline, 6 months, and 12 months. Blood samples will be collected at these time points to measure NfL protein levels and analyze their relationship to MS relapses, disability scores, prior therapies, and other health factors. During the study, participants will complete satisfaction questionnaires and undergo blood tests at scheduled visits. Researchers will monitor adverse events and track various health indicators including MRI lesion counts and other biomarkers. The main outcome is participant satisfaction at 12 months, with additional assessments at earlier time points. This observational study lasts up to one year, with ongoing collection of safety and disease activity data during that time.

Age: 18Years +All Genders
93 locations
R

Actively Recruiting

Researchers are evaluating the effects of inclisiran in people with serious heart conditions known as acute coronary syndromes ACS, including STEMI or NSTEMI, when this treatment is started early after hospital admission. The study compares inclisiran to a placebo, both given alongside standard treatment, to understand its impact. This is a randomized, double-blind, placebo-controlled clinical trial involving two groups. Participants will receive either inclisiran sodium 300 mg or a matching placebo by subcutaneous injection at randomization Day 1 and again on Day 90. The treatment is given on top of standard treatments, including high-intensity statins or non-statin therapies for those intolerant to statins. The study includes a screening visit within 7 days of hospital admission, randomization before or at discharge, a 150-day double-blind treatment period, scheduled safety calls between visits, and a safety follow-up call 30 days after the end of the study. During the study, participants will have assessments of LDL cholesterol and other blood lipids at multiple time points, including baseline, Day 30, Day 90, and Day 150. Safety and efficacy will be closely monitored through visits and telephone calls. The primary outcome measured is the percent change in LDL cholesterol from baseline to Day 150. The total participation duration is approximately 150 days with careful follow-up to evaluate the treatment effects and safety.

Age: 18Years +All GendersPhase 3
69 locations